AE 37
Alternative Names: AE37; AE37 peptide/GM-CSF HER2 peptide vaccine; AE37 vaccine; Cancer vaccine AE37 - Generex-Biotechnology; Cancer vaccine AE37 - NuGenerex Imuuno-Oncology; Cancer vaccine HER2/neu Antigen Express AE37; Cancer vaccine HER2/neu Generex Biotechnology AE37; Her-2/neu Breast cancer; Her-2/neu Prostate cancer; Ii-key hybrid cancer vaccine AE37; Ii-key hybrid HER2/neu vaccine Antigen Express AE37; Ii-key hybrid HER2/neu vaccine Generex Biotechnology AE37; Ii-Key/Her-2/neu(776-790) vaccine; Modified HER2/neu peptide AE37 vaccineLatest Information Update: 27 Apr 2022
At a glance
- Originator Antigen Express
- Developer Antigen Express; Merck AG; NSABP Foundation; NuGenerex Immuno-Oncology
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Breast cancer; Triple negative breast cancer
- No development reported Prostate cancer
- Discontinued Ovarian cancer
Most Recent Events
- 27 Apr 2022 AE 37 is still in phase II trial in Triple negative Breast cancer (Combination therapy, Metastatic disease, Late-stage disease) in USA (Intradermal) (NCT04024800)
- 09 Dec 2021 Efficacy data from a phase IIb trial in Breast cancer presented at the San Antonio Breast Cancer Symposium (SABCS-2021)
- 09 Dec 2021 Greenwich LifeSciences plans a phase III trial in Breast cancer, by 2022